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Original Clinical ScienceçLiver

Effect of Early Everolimus-Facilitated Reduction of
Tacrolimus on Efficacy and Renal Function in De
Novo Liver Transplant Recipients: 24-Month
Results for the North American Subpopulation
William C. Chapman, MD,1 Robert S. Brown, Jr, MD,2 Kenneth D. Chavin, MD,3 Debra Sudan, MD,4
Baburao Koneru, MD,5 Guido Junge, MD,6 Gaohong Dong, PhD,7 Dharmesh Patel, MD,7 Lewis Teperman, MD,8
and John J. Fung, MD9
Background. A recent randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus plus

reduced-dose tacrolimus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compromising
efficacy. In that study, patients from North America (n = 211) had increased risk factors for posttransplant renal insufficiency at study
start, relative to patients from Europe and rest of world (eg, worse renal function, more diabetes, older age). Methods. A post hoc
analysis was performed to assess whether these regional disparities affected study outcomes in North American patients. Results.
In this subpopulation, estimated glomerular filtration rates at randomization were higher in TAC-C over EVR + rTAC (76.4 vs 69.3 mL/
min per 1.73 m2). Mean changes in estimated glomerular filtration rate values (mL/min per 1.73 m2) favored EVR + rTAC over TAC-C
at months 12 (+3.7 vs −4.5; P = 0.032), 24 (+2.7 vs −6.6; P = 0.042), and 36 (+4.3 vs −8.1; P = 0.059). The composite efficacy
endpoint of treated biopsy-proven acute rejection, graft loss, or death was 10.9%, 14.1%, and 14.1% for EVR + rTAC and 13.1%,
17.2%, and 19.3% for TAC-C at months 12, 24, and 36, respectively. Conclusions. Although the North American cohort had
more comorbidities, results were consistent with the overall population for efficacy and renal function.
(Transplantation 2017;101: 341–349)

L

iver transplantation has become a standard-of-care treatment modality for end-stage liver disease, with excellent
overall 5-year survival rates of around 70% or greater.1
However, one of the persistent challenges in the posttransplant period has been management of renal complications associated with chronic immunosuppression therapy
required to prevent rejection of the transplanted graft. In

the United States, it is estimated that the 5-year incidence of
chronic renal failure after liver transplantation is 18.1%.2
Moreover, patients developing chronic renal failure have an
increased mortality risk that is estimated to be more than 4
times greater than those not developing chronic renal failure.2,3 The vast majority of patients who undergo liver transplantation are currently placed on a calcineurin inhibitor
(CNI)-based immunosuppressive regimen, and this is a factor
associated with an increased risk of renal dysfunction.4
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Strategies to reduce CNI-related nephrotoxicity by early
CNI minimization/elimination are of particular interest in
the field of liver transplantation. Recently, in a 24-month international, randomized, controlled study (H2304) in de novo
liver transplant recipients, it was shown that early everolimus
(EVR)-facilitated tacrolimus (TAC) dose reduction led to
significantly better kidney function versus standard TAC
(TAC-C) without compromising efficacy.5,6 The adjusted
change (via an analysis of covariance model) from randomization in estimated glomerular filtration rate (eGFR),
based on the Modification of Diet in Renal Disease-4 variables (MDRD4) formula,7 favored EVR + reduced TAC
(rTAC) over TAC-C by 8.5 mL/min per 1.73 m2
(P < 0.001) at month 12 and 6.7 mL/min per 1.73 m2
(P = 0.002) at month 24.5,6
There are notable differences in patients undergoing liver
transplantation in North America compared with other regions in the world. For example, in the H2304 study, more
participants from North America compared with Europe
and rest of world (ROW) had hepatitis C virus (HCV) infection.8 This difference is not surprising because previous reports have recognized that HCV infection is known to be
the most common cause of liver transplantation in the
United States.9 In addition, North American participants
from Study H2304 had lower eGFR values, and higher
model for end-stage liver disease (MELD) scores at time of
transplantation, than those from other regions.10 They also
had a higher incidence of diabetes and were older when
compared with individuals from Europe and ROW.8 These
factors are known to be associated with an increased risk
of chronic kidney disease or acute kidney injury. 11,12
Regional variation in patient characteristics after liver transplantation have also previously been reported in the literature.13 Because geographical disparities in risk factors for
posttransplant renal insufficiency could have an impact on
study outcomes, it is important to analyze data for specific
subpopulations to assess results in comparison to the overall
study population. Here we report a post hoc analysis of efficacy, renal function, and adverse event (AE) results for the
H2304 North American subpopulation.
MATERIALS AND METHODS
Methods for Study H2304 were previously published in
detail5 and are briefly summarized here.
Study Design

This 24-month international, randomized, controlled
study in de novo liver transplant recipients compared 3
open-label treatments (Figure 1). An initial 30-day (±5 days)
posttransplantation run-in period with TAC (± mycophenolate mofetil [MMF]) was stratified by pretransplant HCV
status and eGFR (MDRD4). Participants were then randomized (1:1:1) into the treatment groups: EVR (trough concentration [C0] 3-8 ng/mL) plus rTAC (C0 3-5 ng/mL)
(“EVR + rTAC”); EVR (C0 3–8 ng/mL to month 4, then
6–10 ng/mL) plus TAC (C0 3-5 ng/mL), with TAC withdrawal by month 4 (TAC-WD); and standard TAC (C0
8-12 ng/mL to month 4, then 6-10 ng/mL) (“TAC-C”).
EVR was initiated at a dose of 1 mg twice daily, with dose
adjustment to achieve the target C0. All patients received
corticosteroids for a minimum of 180 days. Enrollment
in the TAC-WD arm was prematurely terminated, at the
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recommendation of the independent data monitoring committee, due to higher rejection rates. Thereafter, eligible patients completing the run-in period were randomized 1:1 to
EVR + rTAC or TAC-C. Patients who had already been randomized to the TAC-WD arm converted to local standard
treatment if ≤ 180 days after randomization, or either continued on their assigned treatment or converted to local standard
treatment if longer than 180 days after randomization.
Study Endpoints

The original protocol endpoints were noninferiority of
composite efficacy failure rate of death, graft loss, or loss
to follow-up (primary endpoint) and superior renal function
(coprimary endpoint), as assessed by eGFR (MDRD4), at
month 12. After implementation of the protocol amendment to discontinue enrollment in the TAC-WD arm and
to implement the European Medicines Agency guideline
on clinical investigation of immunosuppressants for solid
organ transplantation,14 the primary and coprimary endpoints were separated into noninferior composite efficacy
failure rate of (a) treated biopsy-proven acute rejection
(tBPAR) (defined as an acute rejection with a locally confirmed rejection activity index of 3 or greater according to
Banff 1997 criteria15 treated with antirejection therapy),
(b) graft loss, or (c) death at month 12 (primary endpoint,
noninferiority margin = 12%), and noninferior renal function
as measured by change in eGFR (MDRD4) from randomization to month 12 (key secondary endpoint, noninferiority margin = −6 mL/min per 1.73 m2).
Patients

Briefly, patients were adult (18-70 years of age) recipients
of a primary liver transplant from a deceased donor and
had received an immunosuppressive regimen containing corticosteroids and TAC 3 to 7 days after liver transplantation,
with 1 or more TAC C0 values of 8 ng/mL or greater in the
week before randomization. The eGFR (MDRD4) at randomization was 30 mL/min per 1.73 m2 or greater. Patients
were excluded for the following reasons: recipients of multiple solid-organ or islet-cell transplants, recipients of a liver
from a living donor or a split liver, history of malignancy of
any organ system within the past 5 years (except nonmetastatic basal or squamous cell carcinoma of the skin or hepatocellular carcinoma), hepatocellular carcinoma not meeting
Milan criteria16,17 at the time of transplantation and any antibody induction therapy. AEs were summarized for the safety
population, which included all randomized patients who received 1 dose or more of study medication. The majority of
discontinuations in the EVR + rTAC and TAC-C groups were
due to AEs; see Results section for further details.
Statistical Analysis

Efficacy and renal function (eGFR) analyses were performed using the intent-to-treat population, which included all randomized patients. eGFR values and changes
from randomization to each visit were compared between
the EVR + rTAC and TAC-C groups using the Wilcoxon
Rank-sum test. Data are primarily presented for the North
American subpopulation; results for the European and
ROW subpopulations are also described for context.
However, it is important to note that the study was not
designed to compare subpopulations from the various
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FIGURE 1. H2304 study design.

regions or to assess outcomes with respect to individual
risk factors. As this was an ad hoc analysis, no formal statistical test was performed.
RESULTS
The following sections focus on the EVR + rTAC and
TAC-C treatment groups; results for the terminated TAC-WD
arm are shown in the tables and figures and briefly summarized within the text.
Patients

Of the 719 randomized patients in the overall population,
211 were from North America (EVR + rTAC [n = 65],
TAC-WD [n = 68], and TAC-C [n = 78]); 419 were from
Europe (EVR + rTAC [n = 149], TAC-WD [n = 138], and
TAC-C [n = 132]); and 89 were from ROW (EVR + rTAC
[n = 31], TAC-WD [n = 25], and TAC-C [n = 33]). Patient disposition for the North American subpopulation is shown
in Figure 2.
Demographic and baseline characteristics for the overall
population and the North American subpopulation were
generally similar across the 3 treatment groups (Table 1). In
the North American subpopulation, mean and median eGFR
values at randomization were lower in the EVR + rTAC
group (69.3 and 66.1 mL/min per 1.73 m2, respectively) than
in the TAC-WD (82.2 and 76.1 mL/min per 1.73 m2) and
TAC-C (76.4 and 73.1 mL/min per 1.73 m2) treatment arms.
As mentioned previously, several other differences were apparent between North American participants and those from
Europe and ROW: mean age (54.8 vs 53.8 and 51.4 years, respectively); diabetes (44% vs 29% and 34%), HCV infection
(49% vs 21% and 37%), mean eGFR values (76.1 vs 78.6 and
83.7 mL/min per 1.73 m2), body mass index (26.1 vs 24.4 and
25.2 kg/m2), and MELD scores (22.7 vs 17.6 and 18.5).
Immunosuppression

At randomization, mean trough levels of TAC were
10.3 ng/mL in the EVR + rTAC group and 9.8 ng/mL in the

TAC-C group (Table 2). At months 12 and 24, mean trough
levels of TAC were within the target ranges both in the
EVR + rTAC group (4.5 and 3.6 ng/mL, respectively; target,
3-5 ng/mL) and TAC-C group (7.7 and 6.7 ng/mL, respectively; target, 6-10 ng/mL). At months 12 and 24, mean
trough levels of EVR were within the target range in the
EVR + rTAC group (5.8 and 6.1 ng/mL, respectively; target,
3-8 ng/mL). Results in Europe were similar to those in North
America; sample sizes in ROW were too limited for
meaningful comparison.
Renal Function

There was an imbalance in renal function at time of randomization with lower values for North America compared
with Europe, as well as within the North American subgroup, thus favoring the TAC-C group with a higher eGFR
at time of randomization. However, at most visits after randomization in North America, treatment with EVR + rTAC
was associated with greater mean eGFR values (Figure 3)
and mean increases in eGFR values (Figure 4), versus
TAC-C treatment, with most mean increases being statistically significant (p < 0.05).
In North America, despite having lower eGFR at randomization, mean eGFR values in the EVR + rTAC group
increased after randomization and were significantly
higher at month 3 versus the TAC-C group (Figure 3). At
month 12, mean eGFR values were 71.5 versus 70.5 mL/
min per 1.73 m2 (P = 0.549), respectively. Corresponding
results at month 24 were 68.4 versus 68.0 mL/min per
1.73 m2 (P = 0.747).
In contrast to mean eGFR values, mean changes in eGFR
values were observed from randomization to each visit in
the EVR + rTAC group, with statistically significant
(P < 0.05) differences favoring EVR + rTAC versus TAC-C
at all visits except week 5 (data not shown) and months 9
and 18 (Figure 4). At month 12, mean changes in eGFR
values were +3.7 versus −4.5 mL/min per 1.73 m2 (P = 0.032)
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FIGURE 2. Patient disposition for North American subpopulation.

for EVR + rTAC and TAC-C, respectively; corresponding median changes were −0.2 versus −6.1 mL/min per 1.73 m2. At
month 24, mean changes in eGFR values were +2.7 versus
−6.6 mL/min per 1.73 m2 (P = 0.042), respectively; corresponding median changes were +1.4 and −9.4 mL/min per 1.73 m2.
The terminated TAC-WD arm had the highest mean eGFR
values throughout the study (82.2, 81.7, and 75.0 mL/min
per 1.73 m2 at randomization, month 12, and month 24, respectively). Mean reductions in eGFR values were observed
from randomization to months 12 and 24 (−3.0 and
−10.0 mL/min per 1.73 m2, respectively); corresponding median changes were −0.2 and −0.6 mL/min per 1.73 m2.
Alternative measures (MDRD6, CKD-EPI, serum creatinine, Nankivell, Cockcroft-Gault, and cystatin C) to calculate eGFR were also assessed. The results were similar to
those reported with MDRD4, that is, significantly better
mean eGFR changes versus TAC-C in almost all cases (data
not shown).
Efficacy

Efficacy results are summarized in Table 3 and Figure 5. In
North America, the Kaplan-Meier incidence rate of the primary composite efficacy endpoint of tBPAR, graft loss, or
death for EVR + rTAC at month 12 and month 24 were
10.9% and 14.1%, respectively, and for TAC-C were
13.1% and 17.2% (Table 3 and Figure 5A).
tBPAR occurred in 4 (6.2%) of 65 patients in the
EVR + rTAC group and 9 (11.5%) of 78 patients in the
TAC-C group at month 12. At month 24, the Kaplan-Meier
incidence rate of tBPAR was 8.1% for EVR + rTAC and
13.2% for TAC-C (Table 3 and Figure 5B).

The terminated TAC-WD arm was associated with the
highest event rate of the primary composite efficacy endpoint, primarily driven by a higher tBPAR rate within
3 months of withdrawal of TAC. The primary composite efficacy endpoint, for example, had Kaplan-Meier incidence
rates of 24.6% and 25.9% at months 12 and 24, respectively.
In Europe and ROW, comparability between the EVR + rTAC
and TAC-C arms was also shown for the above endpoints.
Adverse Events

The most common AEs reported in the North American
subpopulation are shown in Table 4. Throughout the study,
the majority of the most common AEs were reported at a similar incidence in the EVR + rTAC and TAC-C groups. Incidence of specific AEs of interest in the EVR + rTAC and
TAC-C groups were as follows: hypertension (26.2% vs
14.1%, respectively), leukopenia (20.0% vs 7.7%), abdominal pain (12.3% vs 20.5%), nausea (15.4% vs 21.8%),
vomiting (9.2% vs 15.4%), insomnia (6.2% vs 17.9%),
and hyperkalemia (7.7% vs 20.5%). The vast majority of
AEs occurred during the initial year of therapy (Table 4).
AEs affecting the cardiovascular system were reported in 11
(16.9%) patients in the EVR + rTAC group and 14 (17.9%)
patients in the TAC-C group. AEs reported by more than
1 patient in either group (EVR + rTAC vs TAC-C, respectively)
included: angina pectoris (2 [3.1%], 4 [5.1%]), tachycardia
(3 [4.6%], 3 [3.8%]), atrial fibrillation (2 [3.1%], 1 [1.3%]),
coronary artery disease (2 [3.1%], 1 [1.3%]), myocardial ischemia (0, 3 [3.8%]), acute myocardial infarction (0, 2
[2.6%]), and cardiomegaly (2 [3.1%], 0). Diabetes mellitus
was reported as an AE in 5 (7.7%) patients in the EVR + rTAC
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TABLE 1.

Demographic and baseline characteristics of intent-to-treat in the overall H2304 population and the North American subpopulation
North American subpopulation
Characteristics

Total H2304 population

EVR + rTAC (n = 65) TAC-WD (n = 68) TAC-C (n = 78) EVR + rTAC (N = 245) TAC-WD (N = 231) TAC-C (N = 243)

Age: mean ± SD, y
54.2 ± 8.3
Sex, n (%)
Male
47 (72.3)
Female
18 (27.7)
Race, n (%)
White
56 (86.2)
Black
4 (6.2)
Other
5 (7.7)
BMI: mean ± SD, kg/m2
26.5 ± 4.5
HCV positive status, n (%)
31 (47.7)
eGFR (MDRD4) at randomization, mL/min per 1.73 m2
Mean ± SD
69.3 ± 26.1
Median
66.1
Diabetic at randomization, n (%)
28 (43.1)
Primary disease leading to liver transplantation, n (%)
Hepatitis C
29 (44.6)
Alcoholic cirrhosis
13 (20.0)
Hepatocellular carcinoma
4 (6.2)
Cryptogenic cirrhosis
5 (7.7)
Primary biliary cirrhosis
5 (7.7)
Sclerosing cholangitis
0
Hepatitis B
2 (3.1)
Autoimmune liver hepatitis
1 (1.5)
Other
6 (9.2)
MELD score, mean ± SD
22.8 ± 10.8
Donor age, mean ± SD
42.2 ± 16.2
Cold ischemia time: mean ± SD, h
7.4 ± 4.31

55.5 ± 8.5

54.7 ± 7.3

53.6 ± 9.2

53.2 ± 10.8

54.5 ± 8.7

51 (75.0)
17 (25.0)

55 (70.5)
23 (29.5)

180 (73.5)
65 (26.5)

164 (71.0)
67 (29.0)

179 (73.7)
64 (26.3)

54 (79.4)
5 (7.4)
9 (13.2)
26.6 ± 4.5
32 (47.1)

64 (82.1)
8 (10.3)
6 (7.7)
25.4 ± 4.8
41 (52.6)

211 (86.1)
4 (1.6)
30 (12.2)
25.2 ± 4.2
79 (32.2)

196 (84.8)
6 (2.6)
29 (12.6)
25.3 ± 4.3
72 (31.2)

195 (80.2)
9 (3.7)
39 (16.0)
24.5 ± 4.2
76 (31.3)

82.2 ± 39.9
76.1
30 (44.1)

76.4 ± 24.4
73.1
39 (50.0)

81.3 ± 33.3
75.7
87 (35.5)

82.9 ± 37.2
75.7
79 (34.2)

78.8 ± 27.7
77.4
97 (39.9)

27 (39.7)
12 (17.6)
8 (11.8)
2 (2.9)
3 (4.4)
5 (7.4)
3 (4.4)
0
8 (11.8)
22.6 ± 6.4
42.3 ± 17.0
6.4 ± 2.32

36 (46.2)
4 (5.1)
6 (7.7)
7 (9.0)
3 (3.8)
5 (6.4)
2 (2.6)
2 (2.6)
13 (16.7)
22.6 ± 6.2
40.8 ± 15.2
6.5 ± 2.23

61 (24.9)
70 (28.6)
44 (18.0)
7 (2.9)
8 (3.3)
8 (3.3)
16 (6.5)
4 (1.6)
27 (11.0)
19.2 ± 9.0
48.8 ± 18.2
7.9 ± 4.4

55 (23.8)
49 (21.2)
32 (13.9)
11 (4.8)
11 (4.8)
20 (8.7)
17 (7.4)
7 (3.0)
29 (12.6)
19.6 ± 7.5
50.0 ± 18.2
7.1 ± 2.8

56 (23.0)
51 (21.0)
36 (14.8)
18 (7.4)
8 (3.3)
12 (4.9)
15 (6.2)
6 (2.5)
41 (16.9)
19.0 ± 7.6
48.7 ± 17.4
7.6 ± 5.2

a
n = 63, b n = 67, c n = 77.
BMI, body mass index.

group and 4 (5.1%) patients in the TAC-C group. AEs of
lipid metabolism in the EVR + rTAC and TAC-C groups, respectively, included hypercholesterolemia (5 [7.7%], 2
[2.6%]), hyperlipidemia (5 [7.7%], 2 [2.6%]), and hypertriglyceridemia (5 [7.7%], 1 [1.3%]).
Wound infections were infrequent during the study, with
only 2 (3.1%) AE reports in the EVR + rTAC group compared with 0 in the other treatment groups. Proteinuria was
also uncommon: 0 with EVR + rTAC treatment and 1
(1.3%) with TAC-C treatment. A single case of stomatitis
was reported in the EVR + rTAC group. AEs of infections/
infestations occurred at a similar rate between treatments,

with the most common being HCV (23.1% vs 20.5% in
the EVR + rTAC vs TAC-C groups, respectively).
Throughout the study, AEs resulted in the discontinuation
of study medication for 20 (30.8%) patients in the
EVR + rTAC group and 14 (17.9%) patients in the TAC-C
group (Figure 2). The only AEs that led to the discontinuation of more than 1 patient in these treatment groups were
hepatitis C infection/acute hepatitis (n = 2) in the EVR + rTAC
group and renal failure (n = 3), hepatitis C infection (n = 2),
and increased blood creatinine (n = 2) in the TAC-C group.
Most discontinuations resulting from AEs occurred within
6 months of randomization.

TABLE 2.

Tacrolimus trough levels at randomization, month 12 and month 24 in the overall H2304 population and the North
American subpopulation
North American subpopulation
Visit

Randomization/week 4
Month 12
Month 24

Total H2304 population

Statistic

EVR + rTAC (n = 65)

TAC-C (n = 78)

EVR + rTAC (N = 245)

TAC-C (N = 243)

n
Mean (SD)
n
Mean (SD)
n
Mean (SD)

57
10.3 (4.5)
32
4.5 (1.8)
22
3.6 (1.5)

73
9.8 (3.3)
50
7.7 (2.8)
41
6.7 (2.6)

205
10.5 (4.2)
135
4.9 (2.1)
109
4.0 (1.7)

211
10.0 (3.1)
148
7.7 (2.8)
128
7.0 (2.5)
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FIGURE 3. Mean eGFR values (MDRD4 formula) over time in the intent-to-treat North American subpopulation.

In the terminated TAC-WD arm, AEs were reported in
91.2% of North American patients over the course of the
study, the most common of which were diarrhea (25.0%),
abnormal liver function tests (23.5%), abdominal pain
(22.1%), peripheral edema (19.1%), and pyrexia (19.1%).
In Europe and ROW, overall AE and discontinuation
rates were similar to those in North America. The differences in individual AE rates mentioned above were not seen
in Europe, with the exception of a higher incidence of leukopenia in the EVR + rTAC group compared with the TAC-C
group (8.1% vs 1.5%).

the TAC-WD group were followed up to month 48. The
mean change in eGFR from randomization to month 36
was +4.3 versus −8.1 mL/min per 1.73 m2 (P = 0.059) in
the EVR + rTAC and TAC-C groups, respectively. Over
the same time period, the primary composite efficacy failure occurred in 14.1% of patients in the EVR + rTAC
group and 19.3% of patients in the TAC-C group
(P = 0.42). Between months 24 and 36, AEs were reported
in 90.9% and 78.6% of patients and SAEs were reported
in 31.8% and 28.6% of patients, respectively.

3-Year Results

DISCUSSION
This report presents important subset analysis data on patients from North America participating in the H2304 randomized trial investigating the role and benefit of EVR for
TAC dose reduction compared with standard-dose TAC
immunosuppression. The use of EVR with TAC allowed
for substantial and safe TAC reduction with resulting comparable efficacy and improved eGFR at month 12

After the 24-month core study, patients who completed
24-month treatment were offered enrollment into the extension study. After informed consent, in the North
American subpopulation, 22 patients in the EVR + rTAC
group, 15 patients in the TAC-WD group, and 42 patients
in the TAC-C group were followed up until month 36;
14 patients in the EVR + rTAC group and 14 patients in

FIGURE 4. Mean change in eGFR values (MDRD4 formula) from randomization over time in the intent-to-treat North American subpopulation.
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Chapman et al

347

FIGURE 5. Kaplan-Meier plot of the proportion of patients free from (a) the primary composite efficacy endpoint of tBPAR, graft loss, or death
and (b) tBPAR in the intent-to-treat North American subpopulation.

compared with patients treated in the standard TAC control arm. Importantly, the improvement in eGFR was preserved at month 24 and month 36 (albeit the sample size
was limited at this latter time point) with EVR + rTAC, in
comparison to TAC-C. Thus, North American patients exposed to EVR + rTAC, despite having worse renal function

and higher MELD scores at study start, had findings that
were consistent with those of European patients and the previously reported overall population.5,6
North American patients enrolled in the current study had
slightly worse renal function for those randomized to
EVR + rTAC compared with the control TAC arm (eGFR:
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TABLE 3.

Summary of efficacy results at months 12 and 24 in the intent-to-treat North American subpopulation
Month 24a

Month 12

Efficacy parameter, n (%)

tBPAR, graft loss, or death (primary endpoint)
tBPAR
Graft loss or death
Graft loss, death, or loss to follow-up
tBPAR, graft loss, death, or loss to follow-up
a

EVR + rTAC
(n = 65)

TAC-WD
(n = 68)

7 (10.9)a
4 (6.2)
4 (6.3)a
5 (7.7)
8 (12.3)

14 (24.6)a
14 (20.6)
0 (0.0)a
7 (10.3)
21 (30.9)

Risk Difference:
Risk Difference of
TAC-C EVR + rTAC vs TAC-C EVR + rTAC TAC-WD TAC-C EVR + rTAC vs TAC-C
(n = 78)
(95% CI)
(n = 65)
(n = 68) (n = 78)
(95% CI)

10 (13.1)a −2.1 (−12.9 to 8.6) 9 (14.1)
9 (11.5) −5.4 (−14.6 to 3.8) 5 (8.1)
1 (1.3)a
4.9 (−1.5 to 11.4) 5 (7.9)
6 (7.7)
0.0 (−8.8 to 8.8) 11 (16.9)
14 (17.9) −5.6 (−17.3 to 6.0) 15 (23.1)

16 (25.9)
14 (22.5)
3 (5.1)
12 (17.7)
24 (35.3)

13 (17.2) −3.0 (−15.1 to 9.0)
10 (13.2) −5.1 (−15.4 to 5.1)
4 (5.4)
2.5 (−5.9 to 10.9)
8 (10.3) 6.7 (−4.7 to 18.0)
17 (21.8) 1.3 (−12.5 to 15.0)

Kaplan-Meier incidence rate is shown.

69.3 vs 76.4 mL/min per 1.73 m2). These differences can be
attributed to this study being a post hoc analysis on a subgroup of the H2304 study, and so the randomization of subjects was not controlled for the North American cohort. Our
therapeutic drug monitoring data showed that at month 24
mean trough levels of TAC were 3.6 ng/mL in the EVR + rTAC
arm versus 6.7 ng/mL in the TAC-C arm (slightly lower than in
the overall population: ~4.0 and ~7.0 ng/mL, respectively).6
This finding indicates that use of EVR was successful in decreasing CNI exposure. Although the TAC-WD arm was prematurely terminated in this study, it should be noted that
PROTECT, a separate long-term study assessing the effect of
EVR treatment and TAC elimination on renal outcomes in
de novo liver transplant recipients, was successfully continued
for up to 60 months, and reported significantly better renal
function and comparable patient and graft outcomes vs
CNI-based immunosuppression.18
An important goal of the H2304 study was to establish
that EVR for CNI exposure reduction was safe to use after
liver transplantation. In this trial, the primary composite

efficacy failure rate of tBPAR, graft loss, or death was
noninferior with EVR + rTAC versus TAC-C at month 12
(6.7% vs 9.7%) and month 24 (10.3% vs 12.5%).5,6 The
United States Prescribing Information (USPI) states a slightly
different composite efficacy failure endpoint in its evaluation
of this study (ie, tBPAR, graft loss, death, or loss to followup), which also showed noninferiority between the 2 treatment groups (9.0% EVR + rTAC vs 13.6% TAC-C at month
12).19 In the USPI analysis of the composite efficacy failure
endpoint of tBPAR, graft loss, death, or loss to follow-up,19
deaths that occurred after study discontinuation or study
drug discontinuation were also included in the data analysis.
Although this approach was not taken in our intent-to-treat
analysis, there were no North American patients who died after study or study drug discontinuation and, thus, our results
for this endpoint were identical to those using the USPI definition. A previous study found that the incidence of BPAR
was significantly greater with MMF and sirolimus (12.2%)
versus MMF and TAC (4.1%) at 12 months posttransplant,
and that sirolimus was poorly tolerated.20 In the current

TABLE 4.

Patients reporting most common (≥10%) adverse events in safety North American subpopulation
Month 12
Adverse events, n (%)

Any adverse event
Diarrhea
Headache
Hepatitis C
Fatigue
Abdominal pain
Hypertension
Abnormal liver function test
Nausea
Pyrexia
Increased hepatic enzyme
Peripheral edema
Tremor
Vomiting
Insomnia
Leukopenia
Back pain
Hyperkalemia
Nasopharyngitis

Month 24

EVR + rTAC (n = 65)

TAC-WD (n = 68)

TAC-C (n = 78)

EVR + rTAC (n = 65)

TAC-WD (n = 68)

TAC-C (n = 78)

63 (96.9)
11 (16.9)
14 (21.5)
13 (20.0)
12 (18.5)
8 (12.3)
14 (21.5)
9 (13.8)
9 (13.8)
5 (7.7)
9 (13.8)
10 (15.4)
9 (13.8)
4 (6.2)
4 (6.2)
13 (20.0)
5 (7.7)
5 (7.7)
8 (12.3)

63 (92.6)
16 (23.5)
9 (13.2)
11 (16.2)
8 (11.8)
11 (16.2)
9 (13.2)
15 (22.1)
10 (14.7)
11 (16.2)
11 (16.2)
12 (17.6)
5 (7.4)
6 (8.8)
5 (7.4)
4 (5.9)
5 (7.4)
1 (1.5)
4 (5.9)

74 (94.9)
17 (21.8)
18 (23.1)
13 (16.7)
16 (20.5)
12 (15.4)
10 (12.8)
11 (14.1)
15 (19.2)
11 (14.1)
9 (11.5)
7 (9.0)
12 (15.4)
11 (14.1)
9 (11.5)
6 (7.7)
11 (14.1)
16 (20.5)
6 (7.7)

64 (98.5)
14 (21.5)
16 (24.6)
15 (23.1)
15 (23.1)
8 (12.3)
17 (26.2)
10 (15.4)
10 (15.4)
11 (16.9)
10 (15.4)
11 (16.9)
10 (15.4)
6 (9.2)
4 (6.2)
13 (20.0)
7 (10.8)
5 (7.7)
9 (13.8)

62 (91.2)
17 (25.0)
10 (14.7)
12 (17.6)
10 (14.7)
15 (22.1)
10 (14.7)
16 (23.5)
10 (14.7)
13 (19.1)
12 (17.6)
13 (19.1)
5 (7.4)
7 (10.3)
6 (8.8)
4 (5.9)
4 (5.9)
1 (1.5)
5 (7.4)

77 (98.7)
20 (25.6)
21 (26.9)
16 (20.5)
16 (20.5)
16 (20.5)
11 (14.1)
11 (14.1)
17 (21.8)
12 (15.4)
12 (15.4)
10 (12.8)
15 (19.2)
12 (15.4)
14 (17.9)
6 (7.7)
11 (14.1)
16 (20.5)
8 (10.3)

Adverse events shown are those reported in ≥ 10% of patients at either month 12 or month 24. Adverse events are sorted by overall frequency of occurrence at month 24.
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analysis, EVR was well tolerated and tBPAR incidence at
month 12 was lower with EVR + rTAC (6.2%) than with
TAC-C (11.5%).
Important demographic differences were identified in
North American patients when compared with European
and ROW patients. As mentioned previously, patients were
older, had higher body mass index and higher MELD scores
at transplant, and had higher rates of diabetes and HCV infection associated with their chronic liver disease. Given that
the North American patients had higher rates of these comorbidities, it is reassuring that the use of EVR + rTAC allowed
for improved renal preservation in this cohort compared with
the TAC-C arm of the study.
There are limitations to the current study. First, the H2304
study was developed as an international trial with no a priori
plan to compare results across regions as well as between
treatment arms within a given region. Second, the small sample sizes of subpopulations limit the ability to demonstrate
significant differences in some of the outcomes; hence, the
data are presented for the North American population as a
whole. However, this study does demonstrate excellent immunosuppression and renal function outcomes for North
American patients, despite the differences in study cohorts
that existed at baseline. A follow-up study on a larger cohort
of North American patients is warranted. Third, EVR + rTAC
is the only approved regimen to lower TAC exposure in liver
transplant recipients. Other immunosuppressive regimens
are sometimes used to decrease CNI exposure in this population, including TAC + mycophenolic acid; however, the regimen of TAC + mycophenolic acid is not approved in liver
transplantation and so was not investigated as part of the
current study. The use of EVR with mycophenolic acid derivatives without CNIs may be another renal-protective strategy
used in liver transplant recipients.21 Fourth, there were high
rates of discontinuation in both the EVR + rTAC and
TAC-C groups (49.2% vs 32.1%). The higher discontinuation rate in the EVR + rTAC arm might be attributable to
the fact that this is the experimental arm and so clinicians
would have been less familiar with this treatment in comparison to the standard treatment.
CONCLUSIONS
In summary, this report demonstrates that North American
patients enrolled in the H2304 international trial investigating use of EVR to facilitate rTAC for immunosuppression after liver transplant had improved renal function at months
12 and 24 after study enrollment. The North American cohort had higher MELD scores at transplant and higher comorbidities with increased rates of diabetes, HCV, obesity,
and MELD score at time of transplant compared with patients enrolled in Europe and ROW. In addition, patients
randomized to the EVR + rTAC arm of the trial in North
America had worse renal function at baseline compared
with patients in the TAC-C arm of the trial. Nevertheless,
North American patients randomized to EVR + rTAC maintained significantly better renal function (ie, improved mean
change from baseline in eGFR) at month 12 and 24 compared with patients in the standard TAC dosing arm of the
trial. Improvement in renal function was maintained at
month 36. We believe this treatment strategy may allow
for excellent immunosuppression with reduced risks of renal
insufficiency after liver transplantation.
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